Why Exact Sciences Stock Blasted Higher on Tuesday

Exact Sciences (EXAS) shares gained nearly 4% after the company reported record third-quarter revenue of $851 million, a 20% year-over-year increase that significantly surpassed analyst estimates of $811 million. The diagnostics specialist also posted a non-GAAP net income of $0.28 per share, handily beating expectations for a loss, driven by strong performance from Cologuard and Oncotype DX. Following these beats, management raised its 2025 revenue guidance to $3.22 billion-$3.24 billion and adjusted EBITDA guidance to $470 million-$480 million, signaling increased confidence in future growth prospects.

Analysis

Exact Sciences (EXAS) reported a strong third-quarter performance, with record revenue of $851 million, a 20% year-over-year increase, significantly surpassing analyst estimates of less than $811 million. The company also achieved a non-GAAP net income of $0.28 per share, a substantial beat against the expected non-GAAP net loss of $0.03 per share. This robust outperformance led to a nearly 4% stock gain for EXAS, contrasting sharply with the S&P 500's 1.2% decline.

Management attributed these gains to the increasing popularity of its key diagnostic products, Cologuard and Oncotype DX, signaling strong underlying demand. Reflecting this confidence, Exact Sciences raised its full-year 2025 revenue guidance to $3.22 billion-$3.24 billion, up from the prior $3.13 billion-$3.17 billion range. Concurrently, adjusted EBITDA projections for 2025 were also increased to $470 million-$480 million.

The significant upside surprise in both top and bottom-line results, coupled with an optimistic revision of future guidance, suggests a positive trajectory for the company's operational and financial health. This performance indicates strong execution in the cancer screening and diagnostics market, positioning EXAS favorably against broader market headwinds.

Key Decisions for Investors

• Investors should assess Exact Sciences' strong Q3 performance and raised 2025 guidance as indicators of robust operational momentum and positive future outlook.
• Consider the implications of sustained demand for key diagnostic products like Cologuard and Oncotype DX on long-term revenue growth.
• Monitor the company's ability to maintain profitability and further expand market share in the competitive diagnostics sector, especially given its outperformance during broader market weakness.